Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART123 cells |
Synonyms | |
Therapy Description |
CART123 cells are T-cells engineered to express a chimeric antigenic receptor (CAR) targeting CD123 and linked to 4-1BB and CD3zeta signaling domains, which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 24596416). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART123 cells | CART123 cells are T-cells engineered to express a chimeric antigenic receptor (CAR) targeting CD123 and linked to 4-1BB and CD3zeta signaling domains, which potentially enhance antitumor immune response and inhibit tumor growth (PMID: 24596416). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Recruiting | USA | 0 |